EPISODE · Dec 20, 2023 · 50 MIN
Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre
from Blood Cancer Talks · host Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180069.html 2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract) https://ash.confex.com/ash/2023/webprogram/Paper191921.html Chronic Lymphocytic Leukemia 1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063 2. Ibrutinib retreatment in Phase 2 CAPTIVATE study: https://ash.confex.com/ash/2023/webprogram/Paper187128.html Hodgkin Lymphoma 1. S1826 outcomes in older adults: https://ash.confex.com/ash/2023/webprogram/Paper180114.html Diffuse Large B-cell Lymphoma 1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180381.html 2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper177588.html
What this episode covers
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180069.html 2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract) https://ash.confex.com/ash/2023/webprogram/Paper191921.html Chronic Lymphocytic Leukemia 1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063 2. Ibrutinib retreatment in Phase 2 CAPTIVATE study: https://ash.confex.com/ash/2023/webprogram/Paper187128.html Hodgkin Lymphoma 1. S1826 outcomes in older adults: https://ash.confex.com/ash/2023/webprogram/Paper180114.html Diffuse Large B-cell Lymphoma 1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180381.html 2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper177588.html
NOW PLAYING
Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre
No transcript for this episode yet
Similar Episodes
No similar episodes found.